Benzinga  Mar 20  Comment 
In a report published Friday, MLV & Co analyst Vernon T. Bernardino initiated coverage on Rexahn Pharmaceuticals, Inc. (NYSE: RNN) with a Buy rating and $1.25 price target. In the report, MLV & Co noted, "We initiate coverage of Rexahn...
StreetInsider.com  Sep 25  Comment 
LipoScience, Inc. (Nasdaq: LPDX) 63.2% HIGHER; Lab Corp. (NYSE: LH) and LipoScience, Inc. (Nasdaq: LPDX) announced that they entered into a definitive merger agreement under which LabCorp would acquire LipoScience for a purchase price of $5.25...
StreetInsider.com  Sep 24  Comment 
Rexahn (AMEX: RNN) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its drug RX-3117 for the treatment of patients with pancreatic cancer. RX-3117 is a next generation,...
StreetInsider.com  Sep 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/UPDATE%3A+Rexahn+Pharma%27s+%28RNN%29+RX-3117+Granted+FDA+Orphan+Drug+Designation/9857256.html for the full story.
Benzinga  Sep 3  Comment 
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and...
StreetInsider.com  Sep 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rexahn+Pharma+%28RNN%29+Receives+NoA+from+USPTO+Covering+CPMA/9801569.html for the full story.
StreetInsider.com  Jul 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rexahn+Pharmaceuticals+%28RNN%29+Updates+on+Supinoxin+Phase+I%3B+Completes+Enrollment+in+Fourth+Dose+Group/9671923.html for the full story.
SeekingAlpha  May 14  Comment 
By Trevor Lowenthal: Today, we are considering a long position in an emerging small cap called Rexahn Pharmaceuticals (RNN). This company operates within the biopharmaceutical sector, has a $150 million market cap and is listed on the NYSE. One of...
StreetInsider.com  Apr 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rexahn+Pharma+%28RNN%29+Ticks+Higher%3B+Issues+Encouraging+Update+on+RX-21101+Preclinical+Results/9394801.html for the full story.
Benzinga  Apr 21  Comment 
Proprietary nano-polymer conjugate of docetaxel shows increased efficacy and reduced toxicity for this widely used FDA-approved chemo drug ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki